Business
Trading Update and Notice of Results
Trading Update and Notice of Results.
About this update from Probiotix Health Plc
[{"type":"text","content":"\n\n15 July 2025\n \nProBiotix Health plc\n(\"ProBiotix\" or the \"Company\" or, together with its subsidiary, the \"Group\")\n \nTrading Update and Notice of Results \n \nProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce a trading update for the six months ended 30 June 2025.\n \nKey financial highlights*:\n \n· Gross revenue +33% to £1.34m (H1 2024: £1.01m)\n· Gross profit +33% to £748,000 (H1 2024: £564,000)\n· EBITDA loss significantly reduced by 59% to £110,000 (H1 2024: £268,000 loss)\n· Strong cash balance of £1.3m (H1 2024: £865,000)\n· Current order book at record level which augurs well for H2\n \n*Numbers are from unaudited management accounts\n \nProBiotix has delivered a solid performance in the first six months of 2025 with all our key financial metrics ahead of budget, largely driven by increasing demand and awareness of our products. Maintaining the gross profit margin at 55%, despite currency fluctuations, including the weakening of the Dollar against Sterling, is also a pleasing result.\n \nDuring the period our partnership agreement with Kemin China Technology Co. Ltd has developed well, with the first orders now delivered and further repeat sales expected. We are also gaining traction with our recently announced partnership with TopHealth in South Korea, which has been buoyed by a product launch of CholBiome X3 by leading pharmacy influencer network PBros, which should augment further growth in the country. Additional products are planned for 2026.\n \nIn Greece, in collaboration with the Company's own scientific team, our partner, Eifron SA launched its cardiometabolic product Beiofolac Cholesterol with key opinion leaders at the Panhellenic Congress of General Medicine in Greece in late April; this has helped boost awareness of Beiofolac Cholesterol and sales are now gaining significant traction.\n \nOur business in the US continues to move apace. The leading brand, Life Extension®, launched its LPLDL® based \"young gut\" product online and nationwide across a number of drugstore chains, in June. Our key p...